NuScale Power Corporation
SMR · NYSE
Analyst ratings
hold · 9 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | Maintains | Sell | $7.00 |
| April 24, 2026 | B. Riley Securities | Maintains | Buy | $19.00 |
| April 21, 2026 | Citigroup | Maintains | Sell | $9.00 |
| March 18, 2026 | UBS | Maintains | Neutral | $13.00 |
| March 2, 2026 | Citigroup | Maintains | Sell | $11.50 |
| March 2, 2026 | Goldman Sachs | Maintains | Neutral | $14.00 |
| March 2, 2026 | RBC Capital | Maintains | Sector Perform | $14.00 |
| February 27, 2026 | Canaccord Genuity | Maintains | Buy | $25.00 |
| February 24, 2026 | Barclays | Maintains | Equal-Weight | $15.00 |
| February 24, 2026 | Cantor Fitzgerald | Maintains | Overweight | $20.00 |
| December 22, 2025 | B. Riley Securities | Maintains | Buy | $24.00 |
| December 12, 2025 | Goldman Sachs | Maintains | Neutral | $23.00 |
| November 25, 2025 | UBS | Maintains | Neutral | $20.00 |
| November 10, 2025 | RBC Capital | Maintains | Sector Perform | $32.00 |
| October 21, 2025 | Citigroup | Downgrades | Sell | $37.50 |
| September 30, 2025 | B of A Securities | Downgrades | Underperform | $34.00 |
| September 3, 2025 | Canaccord Genuity | Maintains | Buy | $60.00 |
Commercialization timeline and ability to secure binding contracts
NuScale holds the sole NRC-approved small modular reactor design and has advanced partnerships, including a planned 6-gigawatt ENTRA1 and TVA project in the eastern United States. Optimistic analysts, with price targets as high as $25, see a potential power purchase agreement by end of 2026 as a transformative catalyst that could validate the technology at scale.
Truist initiated coverage with a Hold rating and a $10 price target, citing mounting skepticism over NuScale's ability to convert MOUs and partnerships into timely, bankable power purchase agreements. The company has missed revenue estimates significantly, reporting just $0.56 million against a $7 million forecast, reinforcing doubts about near-term commercialization.
Revenue growth trajectory and long-term financial viability
Some analysts project NuScale could reach $389.8 million in revenue and $42.8 million in earnings by 2029, with the most optimistic forecasts reaching $941.3 million in annual revenue. Canaccord Genuity set a $25 price target, implying substantial upside and confidence in eventual large-scale commercial deployments driving meaningful financial performance.
The consensus revenue forecast for fiscal year 2026 has been revised sharply downward from $76.2 million to $59.9 million, while forecast losses have widened. The company carries a net income margin of -2,066.55% and has missed earnings expectations for three consecutive quarters, raising serious questions about the path to profitability.
ENTRA1 partnership integrity and shareholder litigation risk
NuScale's collaboration with ENTRA1 and TVA remains central to its commercialization roadmap, and the ENTRA1 project is viewed by supporters as a potential proof-of-concept deployment that could unlock further contracts. Analysts at B. Riley and Northland maintained buy ratings and price targets of $19, signaling continued confidence in NuScale's strategic partnerships.
A shareholder litigation firm is investigating NuScale for alleged misrepresentation of ENTRA1's experience and capabilities, raising concerns about undisclosed risks and the credibility of NuScale's commercialization roadmap. This legal overhang has amplified selling pressure, with the stock sliding from $11 to the mid-$7 range in under a month.